biotech company Moderna, pioneer in messenger RNA (mRNA) therapies and vaccines, and the Rey Juan Carlos University (URJC) have formalized an agreement for the creation of the ‘Modern Chair-URJC in Epidemiology of Infectious Diseases’, focused on the study of vaccines against covid-19.
The new Chair will allow both parties to work together on the design of a training program aimed at generating knowledge through study of messenger RNA (mRNA) vaccines against Covid-19 and their effects on the immunocompromised population and on patients hospitalized for the disease.
After signing the agreement, which will last for two years and may be extended up to four more years, both parties have the objective of implementing and developing research and teaching activities, as well as projects associated with the Chairas they have indicated in a joint note.
Both institutions insist that this project arose “because of the need to generate new scientific evidence related to the burden of the disease and the possibilities of prevention and treatment offered by the new technologies that are incorporated into our environment”.
The rector of the University, Javier Ramos, and Moderna’s medical director for Spain and Portugal, José María Guillénhave been the people in charge of sealing the agreement this Wednesday on the university campus located in Móstoles.
The rector of the URJC signs the agreement for the new Chair together with the medical director of Moderna/URJC
Scientific investigation
«From the Rey Juan Carlos University, we are convinced that the signing of this agreement with Moderna will allow us to strengthen our scientific research and make a significant contribution to overcoming the challenges posed by the pandemic and to improving people’s health and well-being“, Ramos has highlighted.
For his part, Guillén stressed that the signing of this agreement “reinforces Moderna’s commitment to scientific research and training in the field of health” given “the need to address COVID-19 and answer scientific questions associated with infectious diseases that are vaccine-preventable or potentially vaccine-preventable.”
Two epidemiological studies on respiratory diseases and a medical education activity on disease burden and its prevention, These will be the first activities that both entities will implement within the framework of this Chair of Epidemiology of Infectious Diseases’.
The Rey Juan Carlos University, founded in 1996, is the newest of Madrid’s public universities and currently has nearly 45,000 students enrolled in official degrees at its five campuses: Alcorcón, Aranjuez, Fuenlabrada, Madrid and Móstoles.
For its part, Moderna, in the ten years since its creation, has gone from being a company in the research phase that developed programs in the field of messenger RNA (RNAm) to a company with a diverse clinical portfolio of vaccines and therapies across seven modalities, a broad portfolio of intellectual property, and integrated manufacturing facilities that enable rapid clinical and commercial production at scale.
Related
2023-07-05 11:07:32
#MUNICIPALITIES #URJC #creates #Chair #Moderna #investigate #covid19 #vaccines #News #Municipalities
